Xenon Pharmaceuticals lost nearly a third of its market value Friday after the company stopped enrolling new patients in late-stage depression studies of azetukalner, introducing a new safety concern just as its lead drug reached the Food and Drug Administration for epilepsy.
Shares plunged 30.7% to $39.75, their lowest close in about 10 months, wiping roughly $1.7 billion from Xenon’s market capitalization in a single session.
The selloff followed Xenon’s disclosure that patients in its major depressive disorder and bipolar depression programs experienced neuropsychiatric adverse events including confusion, speech difficulties, impaired coordination and rare episodes characterized as psychosis.
Most of the reported events were mild or moderate, occurred shortly after treatment began or doses changed, and resolved without lasting effects. The rarer psychosis-related events occurred at a rate of roughly 1%, according to information provided by the company.
Xenon described the enrollment halt as temporary and precautionary rather than an FDA-mandated clinical hold.
Patients already participating in the trials will continue receiving treatment. Xenon is evaluating changes to dosing that could reduce the side effects before it resumes recruiting new patients.
The problem for investors is not simply that side effects appeared.
The events were not observed in Xenon’s smaller Phase 2 depression study, meaning the safety profile changed as azetukalner moved into a substantially larger patient population.
That adds uncertainty to what had become one of the most valuable pieces of Xenon’s long-term growth story.
Depression Was Already the Higher-Risk Part of the Program
Azetukalner is a potassium-channel opener designed to reduce excessive neuronal activity.
Its most advanced use is epilepsy, where Xenon has generated positive data across multiple clinical studies and accumulated more than 1,500 patient-years of exposure.
The depression program was more speculative even before Thursday’s disclosure.
In the 168-patient Phase 2 X-NOVA trial, patients receiving 20 milligrams of azetukalner improved by 16.94 points on the Montgomery-Åsberg Depression Rating Scale after six weeks, compared with 13.90 points for placebo.
The 3.04-point advantage was considered clinically meaningful by the researchers but was not statistically significant, with a P value of 0.14.
The study therefore missed its primary endpoint.
Other measurements were more encouraging.
On the 17-item Hamilton Depression Rating Scale, the 20-milligram group improved 13.3 points compared with 10.2 points for placebo, a nominally statistically significant difference.
Azetukalner also produced signals suggesting improvement in anhedonia—the inability to experience pleasure—and a faster onset of antidepressant activity.
Those findings were strong enough for Xenon to move directly into a large Phase 3 program.
The company chose the HAM-D17 scale, where the Phase 2 trial had shown a stronger signal, as the primary efficacy measure for its pivotal major-depression studies.
The new safety observations now complicate that strategy.
Lowering the dose or changing the titration schedule could improve tolerability, but any modification would also need to preserve enough drug exposure to maintain antidepressant efficacy.
Xenon has not yet said what dosing changes it will make.
One Depression Trial Can Still Produce Data
The pause does not mean Xenon has lost all of its near-term depression data.
The X-NOVA2 Phase 3 study had already enrolled about 360 patients, approximately 80% of its original 450-patient target, before recruitment stopped.
Xenon says that population is still statistically large enough to detect a clinically meaningful difference on the trial’s primary HAM-D17 endpoint.
Existing participants will finish the six-week treatment period, after which the study will be unblinded.
Topline results are expected during the first quarter of 2027.
That readout has become much more important.
A strong efficacy result combined with a manageable safety profile could give Xenon a path to redesign later psychiatry studies and resume development.
A weak result would be considerably more damaging because it would arrive after the company has already uncovered tolerability problems that were absent from the earlier trial.
X-NOVA3 in major depression and Xenon’s X-CEED bipolar depression studies remain affected by the enrollment pause.
Epilepsy Is Still Moving Toward Approval
The timing of the psychiatry setback overshadowed what would otherwise have been one of Xenon’s biggest milestones.
The company submitted a New Drug Application to the FDA for azetukalner as an adjunctive treatment for focal seizures.
The application is supported by the Phase 2b X-TOLE and Phase 3 X-TOLE2 trials, where all four tested doses across the two studies produced statistically significant reductions in monthly seizure frequency compared with placebo.
Xenon says azetukalner demonstrated a consistent and generally well-tolerated safety profile across its epilepsy program.
The company is also continuing its X-TOLE3 focal-seizure trial and X-ACKT study in primary generalized tonic-clonic seizures.
Neither program is affected by the psychiatry enrollment pause.
That separation explains why Friday’s decline, while severe, does not mean the market is assigning zero value to azetukalner.
Epilepsy remains the nearest commercial opportunity.
Focal epilepsy is the most common form of the disorder, and Xenon estimates that as many as half of patients continue experiencing uncontrolled seizures despite the availability of more than 30 antiseizure medications.
If approved, azetukalner would become Xenon’s first commercial product.
The psychiatry program had offered something additional: the possibility that the same drug could eventually address much larger populations in major depression and bipolar depression.
Friday’s repricing reflects uncertainty around that second part of the story.
Competitors Have Their Own Safety Questions
The setback also changes the competitive picture for other companies developing potassium-channel drugs.
Biohaven is developing opakalim, another Kv7-targeting therapy, for epilepsy and psychiatric conditions.
Its program is not free of regulatory risk.
Earlier this month, the FDA placed a partial clinical hold on new enrollment in Biohaven’s opakalim program while the company investigates findings involving a metabolite observed in animal studies.
Patients already enrolled remain on treatment, and one pivotal epilepsy trial had completed enrollment before the hold.
Biohaven shares rose only modestly as Xenon collapsed Friday, suggesting investors are not treating Xenon’s setback as an automatic competitive victory.
The two programs now have different uncertainties: Xenon has clinical neuropsychiatric observations in human patients, while Biohaven is working through an unresolved preclinical safety issue.
Xenon Has the Cash to Work Through the Setback
Funding is not the immediate problem.
Xenon ended June with approximately $1.25 billion in cash, cash equivalents and marketable securities.
The company lost $110.7 million during the second quarter and $213 million during the first six months of 2026 as research spending increased, but its balance sheet gives it substantial capacity to continue the epilepsy launch effort and redesign the psychiatry program without immediately needing another equity raise.
That shifts the next major risk back to clinical and regulatory execution.
The FDA must first decide whether to accept Xenon’s epilepsy application for review. If the filing moves forward, investors will begin focusing on the regulatory timeline and the commercial profile of azetukalner in focal seizures.
Depression has a more immediate binary event.
X-NOVA2 data are still expected in the first quarter of 2027 despite the enrollment pause.
That trial now needs to answer two questions simultaneously: whether azetukalner meaningfully improves depression and whether the efficacy is strong enough to justify working around the neuropsychiatric effects that emerged as Xenon treated more patients.
Until then, epilepsy remains intact, but the much larger expansion story investors had been assigning to azetukalner has become considerably harder to value.